Commercial kits give different measurements for concentrations of growth hormone (GH, somatotropin) in serum. Most notably, a two-site monoclonal-antibody-based immunoradiometric assay (IRMA) from Hybntech routinely yields lower values than do conventional AlAs in which polyclonal antibodies are used. We used purified dimeric biosynthetic human GH as a model compound to investigate the specificity of five commercial immunoassays for size variants of GH. In all five assays, biosynthetic monomeric GH was significantly more potent than pituitary-derived standard GH supplied with the kits. Dimeric GH was significantly less potent than monomer in four of the five assays, and crossreactivities varied more than fivefold, from 15% to 84%. Using three commercial kits selected for their specificity for dimeric GH, we measured GH in serum samples from 18 normal adults. The mean GH concentrations in serum-O.7 (Hybritech, IRMA), 1.8 (Diagnostic Products, RiA), and 3.1 (Cambridge, AlA) /L-differed significantly, but in the same rank order as that obtained in the experiments on dimer cross-reactivity. The diagnosis of growth hormone (GH, somatotropin) deficiency has traditionally been based on radioimmunoassay (RIA) of GH in serum during stimulation-based tests for secretion of pituitary GH (1, 2). However, different commercial immunoassays have detected different GH concentrations (3-9). Most notably, a two-site monoclonalantibody-based immunoradiometric assay (IRMA) from Hybntech routinely
heterogeneous mixture of genetically related proteins, varying both in size and charge (10) (11) (12) . GH size variants have been characterized as an oligomeric series of GH monomers (13) , which can be released from the pituitary by physiological or pharmacological stimuli (14) (15) (16) . Both noncovalent and covalent forms of dimeric GH have been described in serum and in extracts of pituitary gland (13,
17-19).
GH fragments may constitutea major fraction of the total GH immunoreactivity present in serum during nonstimulated periods (15) . Additionally, a 20-kDa variant form that lacks residues 32-46 constitutes about 5% of circulating GH (20) .
We used dimeric GH purified from production lots of biosynthetic human GH as a model compound to investigate the cross-reactivity of GH size variants in commercial diagnostic kits. These kits differ substantially in their ability to detect the monomeric and dimeric forms of biosynthetic GH and, presumably, in their ability to cope with the molecular heterogeneity of circulating GH.
Materials and Methods
Growth hormone. The purified recombinant DNA-derived human GH used in this study was prepared at Eli Lilly & Co., Indianapolis, IN. This biosynthetic GH is structurally, physically, antigenically, and biologically equivalent to pituitary-derived
GH (21-23).
The preparation and the characterization of a GH reference standard have been described elsewhere (24) , as have purification and characterization of a dimeric form of biosynthetic GH (21) . In brief, dimeric GH, purified by size-exclusion chromatography and anion-exchange chromatography, is a noncovalent form that dissociates into monomer in the presence ofdetergents or acetonitrile (300 mLIL). In bioassays, purified dimer displays less activity than monomeric GH, and it was characterized as the dominant dimeric species present in production lots of both biosynthetic and pituitary-derived GH (21).
GH immunoassays.
The cross-reactivity of monomeric and dimeric biosynthetic GH was evaluated in commercial In each commercial kit, pituitary-derived GH is the reference standard used for estimating concentrations of GH in serum. Assays 2 through 4 include GH standards calibrated against the WHO reference preparation 66/217, whereas the kit standards in Assays 1 and 5 are calibrated against the NIH reference preparations AFP-4793B and HS-2243E, respectively. In each RIA kitthe bound fraction of labeled GH is quantified after separation by a secondantibody precipitation method. The IRMA makes use of antibody-coated plastic beads as a separation method. For cross-reactivity experiments with biosynthetic GH, we used reference preparations of monomer (lot no. RS0035) and purified dimer (lot no. P45-J67-168D-1). Fresh stock solutions (1 mg/mL) of monomer and dimer were prepared daily in 25 mmolJL sodium phosphate, pH 7.5, and their protein concentrations were verified spectrophotometrically. To prepare standard curves, we diluted each stock solution in the assay matrix supplied for the kit standard GH. We analyzed each standard concentration of monomer, dimer, or kit-supplied GH in triplicate and performed all assays in accordance with the vendors' instructions. Bound radioactivity was measured for 2 mm in an automatic gamma counter (Apex 10/600; ICN Micromedic Systems, Inc., Horsham, PA). Commercial immunoassay controls (Lyphocheck 1-ifi, master lot no. 2000; Bio-Rad Labs., Richmond, CA) were used to validate the accuracy of each immunoassay.
Data analysis.
RIA data were plotted log-linear, fitted with a four-parameter logistic model algorithm, and analyzed statistically with the computer program ALLFI'F (25). In this program, the ED50 is defined as the concentration of GH necessary to displace 50% of bound labeled GH. Relative potency estimates were then calculated from the ratios of the EDso values for monomeric and dimeric GH. The value for the slope estimated for each displacement curve by ium corresponds to the slope estimate derived from a logit-log transformation.
IRMA data were plotted linearlinear, as recommended by the kit's vendor, and then fitted by use of a linear-regression equation. Potency estimates for monomeric and dimeric GH in the IRMA were calculated from the ratios of the slopes.
We calculated GH concentrations in serum for the commercial RLAs by using a weighted four-parameter logistic model curve-fitting program, "RIASYS," developed at Eli Lilly & Co. For the nu they were estimated by using an IBM-PC-based immunoassay data-reduction system (IsoData, Inc., Rolling Meadows, IL) with a French curve algorithm. We compared the concentrations obtained with each commercial kit statistically by using a nonparametric binomial sign test for paired observations (26) . Differences were defined to be statistically significant at P <0.05.
Results

Figure 1 shows the displacement curves for monomeric
and dimeric biosynthetic GH in each commercial RIA kit; in all cases, monomeric and dimeric biosynthetic GH displaced labeled GH in a manner parallel to kit-supplied standard GH. Figure 2 shows the cross-reactivity of monomer and dimer in the IRMA. In all five assays, biosynthetic monomeric GH was significantly more potent than pituitary-derived kit-supplied standard GH, with cross-reactivities ranging from 133% to 220% (Table 1) . In all assays except Assay 1, dimeric GH was significantly less potent than monomer, with cross-reactivities ranging from 15% to 84% (Table 2 ). The potency estimates for dimeric GH in the commercial kits were also more variable than those for the monomer.
Because of the fivefold difference we found in dimer cross-reactivity, we measured the GH concentrations in serum samples obtained from 18 unselected, ostensibly normal adults, using three different commercial kits. Assays 1, 2, and 5 were selected because of their wide specificity for dimeric GH. The mean serum GH concentrations found were 3.1, 1. Significant at a p <0.05 and b P <0.001. basis for this discrepancyremains unresolved. Furthermore, these analytical differences have raised concerns regarding the applicability of a 10 nglmL cutoff value for GH deficiency to all immunoassays (8) . The molecular heterogeneity of circulating GH may be one factor affecting measurement of GH by immunoassays. However, the lack of availability of purified GH size variants has precluded investigating the hypothesis in detail. We used dimeric GH purified from production lots of recombinant GH as a model compound to investigate the specificity of commercial immunoassays for size variants. We performed preliminary experiments to define the approximate potencies of biosynthetic monomeric and dimeric GH in the commercial kits. For each commercial immunoassay kit we optimized the range of GH concentrations to permit analysis of the data by ALLFIT (25) . In all cases of the values for the EDso and the slope in the RIA kits ranged from 9.5% to 16.0%. In each case we obtained the same rank order for the potencies of monomeric, dimeric, and kit-supplied standard GH. In each lilA, monomeric and dimeric biosynthetic GH displaced labeled GH parallel to pituitary-derived kit standard GH. As shown in Figures 1 and 2 and summarized in Table 1 , biosynthetic monomeric GH was significantly more potent than kit Standard GH in all five of the commercial assays.
Monomer cross-reactivities
ranged from 133% with Assay 1 to 220% obtained with Assay 4. The differences in the cross-reactivity of monomeric GH suggest that differences in pituitary-derived Gil reference standard may contribute to the discordance in values seen with commercial kits. However, major differences in the kit standard matrices precluded performing an inter-assay comparison of kit standard GH. Size variant forms of GH are present in clinical-grade preparations of pituitary GH (26). Biosynthetic monomeric GH also has greater potency on a weight basis than does standard pituitary-derived GH in bioassays (21, 23) . The greater potency of biosynthetic GH in cornmercial assays may result from its higher purity (22, 23) . Thus, biosynthetic GH may be superior to pituitary-derived GH as a reference material in commercial immunoassays. The use of biosynthetic GH as an immunoassay standard would result in lower values for apparent GH in serum by a factor of two, owing to its higher potency (4).
The potency of biosynthetic dimeric GH varied more than fivefold in the commercial kits (Table 2) . Dimer cross-reactivity could be grouped roughly into one of three categories. In Assay 1, dimer potency was not significantly different from monomer. In Assays 2-4, dimer cross-reacted about one-third as well as did monomer. In Assay 5, dimer only cross-reacted 15% as well as monomer. Thus, the Hybritech mr.t is a relatively specific assay for monomeric GH. The decreased dimer cross-reactivity in the MA may reflect a superior analytical specificity resulting from the use of monoclonal antibodies. 5, 6, 9) . Additionally, the 20-kDa variant form of GH, which does not cross-react in the Hybritech tiuvi, displays varying cross-reactivity in other IRMAS (7, 9) . Thus, all mr.s are not equivalent, which suggests that the selection of GH monoclonal antibodies is of pivotal importance for maximizing assay specificity for monomeric Gil.
Using three different commercial kits, we measured the GH concentrations in serum samples obtained randomly from 18 normal adults. Assays 1, 2, and 5 were selected on the basis of their wide range of specificity for dimeric GH. The GH concentrations obtained with Assay 5 were significantly lower than the concentrations found with Assay 1 (Figure 3) . Thus, we demonstrated a difference in apparent concentrations in serum as a result ofanalytical differences in commercial GH immunoassays. These data also support the results obtained in the cross-reactivity experiments. The highest mean concentration of Gil in serum was found with Assay 1, the assay having the greatest dimer crossreactivity.
The assay displaying the lowest dimer crossreactivity, Assay 5, also yielded the lowest mean value for GH in serum.
In summary,
we have examined the specificity of five commercial GH immunoassays with recombinant DNAderived monomeric and dimeric Gil, the objective being to investigate a potential mechanism for the discordance in GH concentrations measured with commercial kits. A better understanding of these analytical differences will permit better clinical application of these methods in the diagnosis of disorders of Gil secretion. We found that commercial kits differed substantially in their ability to detect both the monomeric and dimeric forms of biosynthetic GH. Thus, we recommend that biosynthetic monomeric GH be used as the reference material in commercial kits to assess Gil deficiency. This should improve calibration and decrease kit-to-kit variability.
The Hybritech kit was unique in that it was relatively specific for monomeric Gil, the predominant biologically active form in vivo. The lower values for serum Gil obtained with the Hybritech IRMA suggest that the molecular heterogeneity of circulating Gil contributes to the discrepancies among commercial diagnostic kits. Received September 28, 1989; accepted November 17, 1989. used as reference materials and as external quality-asaurance materials for cholesterol and apolipoproteins (1, 2). These materials are stable during long-term storage and shipment and are relatively inexpensive to mail. Recently, in a study on the effect of lyophilization of serum pools on the determination of cholesterol, the measured concentration of cholesterol was shown to be less for lyophilized serum than for frozen serum, and the decrease in the original cholesterol value varied depending on the cholesterol assay method (3). In our experience, if a pooled specimen of serum was stored frozen and used as a common calibrator for methods differing in principles and antibody source, essentially identical apo A-I and B values were obtained for fresh samples of normolipidemic sera. Despite agreement on patients' samples, however, we found that with a serum pool in lyophilized form prepared as candidate Reference Material by the Centers for Disease Control (CDC) (pool 1883), there was about a 30% difference between ape B values obtained by radial immunodiffusion (RID) and those obtained by nephelometry. Therefore, one aim of the present study was to verify whether the differences obtained with CDC material were unique to the CDC material or common to other lyophilized materials. Furthermore, we exanuned the suitability of lyophilized material as a common reference material for use in measurements of apo A-I and B.
Materials and Methods
Serum Pools
Lyophilized pools used as calibrators of commercially available kits for ape A-I and B were obtained from seven different companies. Candidate serum reference pool for ape A-I and B was obtained from the CDC (pool 1883). Nine fresh-frozen and lyophilized serum pools were prepared as follows. For each serum pool, 2 mL of serum were obtained from each of 50 patients who had been pre-screened for cholesterol and triglyceride concentrations. All serum pools were made from subjects whose triglyceride concentration was <1.4 gIL. Serum with low triglyceride concentrations was selected because artifacts in ape B measurements can occur with hypertriglyceridemic samples (4). The low-, normal-, and high-concentration pools were obtained by pooling specimens from patients whose cholesterol concentrations were, respectively, <2.0 g/L, between 2.0 and 2.4 gIL, and >2.4 g/L. Each pool was divided into 1-mL aliquots by a Micromedic dispenser and quick-frozen in individual vials at -78 #{176}C. Half of the vials were kept frozen at
